1. In your view, what are the most transformative innovations in bioprocessing over the last five years, and how are they reshaping drug development pipelines?
Bioprocessing has undergone a remarkable shift in recent years, driven by technologies that enable faster, smarter, and more controlled development than ever before. The biggest change is our ability to generate deep process understanding at a far earlier stage, accelerating innovation, streamlining development, and ultimately helping breakthrough therapies reach patients sooner. This transformation is not happening in isolation; it is taking place in close collaboration with a rapidly evolving ecosystem of partners, from established manufacturers to emerging biotech hubs in markets such as India, which is becoming a co-creator of advanced therapies rather than just a production base.
We’ve seen this transformation play out most clearly across three areas. First, upstream titers have increased dramatically, allowing the industry to move toward intensified, higher-productivity downstream processes and address long-standing purification constraints.
Second, the emergence of continuous and hybrid processing has enabled more predictable, higher-quality outputs, with real-time adjustments increasingly replacing lengthy batch cycles.
Finally, the adoption of single-use technologies has introduced a new level of flexibility, particularly for multi-product facilities and operations working with emerging modalities.
Together, these advancements are reshaping the development pipeline, reducing facility footprints, shortening turnaround times, and enabling more cost-efficient manufacturing at scale. When combined with investments in regional innovation and manufacturing hubs—the sites that serve as strategic centers for R&D, manufacturing and exports—these technologies are helping to build a more distributed, resilient, and innovation‑driven global bioprocessing ecosystem.
2. How is artificial intelligence changing the landscape of bioprocess optimisation, and what are the tangible impacts on speed, efficiency, and predictive outcomes in drug manufacturing?
Artificial intelligence is rapidly becoming foundational to how biologics are developed and manufactured, with its impact now clearly visible in the speed, efficiency, and predictability of modern bioprocessing.
For speed, facilities across the region have gradually evolved into hubs for technology transfer and workforce training, accelerating the adoption of next-generation bioprocess technologies. Digital twins are able to simulate process performance in minutes, enabling teams to scale with greater confidence and compress development timelines in ways that would have been unimaginable just a few years ago.
Such regional hubs play a critical role in deploying an AI-enabled approach faster and consistently across sites, supporting translation from development to manufacturing while maintaining process robustness.
On the efficiency front, these facilities are engineered as a benchmark for streamlined, digitally enabled manufacturing. Integrated digital systems harmonize production workflows and strengthen consistency across global supply chains. AI-powered control layers automate documentation, QC activities, and pattern recognition across vast datasets, reducing manual burden and minimizing operator-driven deviations. Predictive-maintenance tools flag equipment issues before they escalate, resulting in fewer batch failures, higher equipment utilization, and a far steadier manufacturing rhythm.
AI’s most transformative contribution lies in its predictive capabilities, spanning discovery through commercial manufacturing. Machine-learning models can now anticipate process drift, shifts in cell metabolism, and emerging critical quality attributes well before they appear in routine analytics. This allows teams to intervene proactively rather than reactively, significantly improving batch-to-batch reliability and process robustness. Together, these advances represent a meaningful step toward truly predictive and resilient bioprocessing.
Beyond manufacturing and bioprocess optimisation, AI is also reshaping earlier stages of development. Advanced predictive models can rapidly assess molecular and formulation options, reduce experimental burden and material use while accelerating promising candidates toward clinical development.
3. Can you discuss specific examples where digital manufacturing platforms have enhanced operational resilience and scalability in biopharma?
Rising demand for new therapies, cost pressures, and the rapid emergence of novel modalities are pushing biopharma toward smarter, more resilient manufacturing models. At the core of this evolution are digital platforms that unify equipment, analytics, and automation into a connected ecosystem. Technologies such as digital twins, real-time analytics, and predictive maintenance enable teams to identify issues early, respond quickly to process or supply-chain disruptions, and shift from reactive troubleshooting to proactive control. The result is lower downtime, fewer batch failures, and a far more robust, continuous operational flow.
These digital backbones are also redefining what scalable manufacturing looks like. By integrating automation, PAT, and continuous data capture, they enable intensified and connected workflows across both upstream and downstream operations. This not only simplifies scale-up without major process redesign but also streamlines technology transfer and strengthens consistency across global sites. At the same time, data‑driven optimisation of process parameters and workflows supports higher yields, improved resource utilisation, elevated process control, and increased throughput—moving beyond simply avoiding failures to actively enhancing performance.
From accelerated seed-train intensification to more efficient harvest and purification, digital systems reduce manual intervention, increase throughput, and help manufacturers respond faster to market demands, while maintaining rigorous compliance in a highly regulated environment.
This approach is exemplified by integrated manufacturing frameworks that connect intensified upstream processing with downstream harvest, purification, and filtration. In-line Raman process analytical technologies, combined with automated sampling and closed-loop control, help stabilise intensified upstream operations and extend control into downstream steps, reducing deviations and unplanned downtime.
Centralised analytics that aggregate sensor, PAT, and batch data enable faster identification of root causes, while modular automation architectures increasingly support plug-and-produce scale-out and copy-exact recipe transfer. Together, these capabilities allow capacity to be added with minimal disruption while maintaining process consistency.
Looking ahead, the combination of digital twins for steps such as TFF yield optimisation, predictive maintenance, and smart consumables will further increase throughput, shorten changeovers, and lift batches per year at consistent quality. Together, these capabilities strengthen operational resilience and scalable capacity, and we are continuing to develop our digital bioprocessing excellence services and applications—such as digital‑twin‑based optimisation, predictive maintenance, and smart consumables—to help customers unlock even greater performance from their bioprocessing operations.
4. What strategic considerations should companies prioritise when expanding bioprocessing capabilities across global markets, especially in emerging economies?
As bioprocessing expands into new and emerging markets, it’s increasingly clear that there is no one-size-fits-all model. Each region brings its own regulatory landscape, infrastructure constraints, and patient needs. Real success comes from understanding these nuances deeply and designing solutions that align with them. By collaborating with local partners, sharing expertise, and deploying the right technologies, companies can scale more efficiently and sustainably, while delivering meaningful benefits to communities and patients worldwide.
We’ve seen that combining investments in manufacturing capacity with in-region technical training and collaboration centers is critical to building sustainable bioprocessing ecosystems.
Successful expansion requires a balanced strategy, one that blends global expertise with deep local insight, strong partnerships, technology readiness, and a commitment to building sustainable, future-ready bioprocessing ecosystems.
5. With accelerated innovations in bioprocessing, how can biopharma organisations effectively navigate regulatory challenges while maintaining speed-to-market?
In a landscape where bioprocessing technologies are evolving at unprecedented speed, the true differentiator for biopharma companies is their ability to innovate while staying fully aligned with shifting regulatory expectations.
The most effective way to balance speed with compliance is to embed regulatory thinking from the earliest stages of development, rather than treating it as a late-stage checkpoint. This includes adopting quality-by-design principles, establishing rigorous documentation frameworks, and leveraging digital systems that provide end-to-end traceability from the moment a process is conceived.
AI-driven analytics, digital twins, and advanced process-monitoring tools now give teams deeper process insight and faster decision-making, resulting in clearer, more comprehensive, and more defensible regulatory submissions. In parallel, close collaboration with regulatory experts, CDMOs, and technology partners ensures that documentation aligns with global standards, reduces iterative back-and-forth, and keeps development timelines on track.
6. How are emerging bioprocess technologies addressing environmental sustainability and cost efficiency in large-scale production?
Emerging bioprocess technologies are no longer just about being ‘less harmful’, they are engineered to embed sustainability at the very core of process design. By integrating process intensification, single-use flexibility, and smarter supply-chain strategies, the industry is moving toward a more circular model of biomanufacturing: reducing waste, energy use, and water consumption, lowering carbon footprint, and delivering high-quality biologics more efficiently and at lower cost.
Innovative bioprocessing technologies, from single-use systems and intensified bioreactors to advanced harvesting solutions and circular supply chains, are reshaping large-scale biomanufacturing. They allow companies to boost cost competitiveness, increase operational agility, and significantly reduce environmental impact. For organisations committed to sustainable growth, these technologies make it possible to meet financial and environmental goals without compromising on quality, safety, or regulatory compliance.
7. What role do partnerships between biotech startups, tech companies, and traditional pharma play in advancing cutting-edge bioprocessing technologies?
Partnerships are increasingly a driving force in the evolution of bioprocessing. When biotech startups, technology innovators, and established pharmaceutical companies collaborate, each brings distinct strengths: startups contribute agility and fresh perspectives, technology firms add digital and data expertise, and established pharma provides scale, experience, and rigorous quality standards.
This synergy not only accelerates innovation but also makes it more efficient and less risky. By working together across the ecosystem, organisations can translate breakthroughs from the laboratory to patients faster and with greater reliability.
Collaborative partnerships allow organisations to share resources, mitigate risk, and accelerate development timelines. Early-stage biotechs, in particular, gain access to advanced R&D facilities, global networks, and funding, helping promising discoveries bridge the gap between bench research and market-ready manufacturing. These alliances also address the growing complexity of bioprocessing by combining scientific innovation with process engineering and regulatory expertise. The outcome is more efficient biomanufacturing and the ability to deliver high-quality therapies at scale, faster, safer, and more reliably than ever before.
For example, in India we collaborate with the Ministry of Commerce & Industry and Startup India, as well as leading CDMOs and incubators, to support emerging biotechs with access to state-of-the-art laboratories, biomanufacturing technologies, and end-to-end mentorship—helping them navigate the “valley of death” between early innovation and scalable production.
In short, cross-sector partnerships are the backbone of modern biotech innovation. They transform breakthrough science into tangible impact, ensuring next-generation therapies reach patients sooner, more sustainably, and with enduring quality.
8. How do companies balance the adoption of disruptive technologies with the operational risks inherent in highly regulated biomanufacturing environments?
Striking the right balance between disruptive technologies and regulatory standards is critical in biomanufacturing. Both innovation and compliance are essential, and leaning too far toward either can introduce risk. On one side, technologies like AI, automation, and digital twins are transforming how therapies are discovered, developed, and manufactured, enabling faster workflows, reducing errors, and unlocking possibilities that were unimaginable a decade ago. On the other hand, patient safety, data integrity, and regulatory compliance remain non-negotiable.
The solution is not choosing between innovation and compliance but integrating them. Companies that embed regulatory frameworks early in the innovation process, rather than treating them as downstream checkpoints, operate more effectively in highly regulated environments. By engaging regulators throughout development and treating them as partners rather than gatekeepers, organisations can drive innovation while maintaining the highest standards of safety and quality.
Technology itself has become a key enabler of compliance. AI-driven analytics, automated documentation, and digital quality systems allow teams to innovate while maintaining data accuracy, transparency, and traceability. At the same time, continuous training and cross-functional collaboration ensure that scientists, engineers, and regulatory teams operate with a shared understanding.
A striking example of this was seen during COVID-19 vaccine development. Speed and innovation were essential, but so was public trust. The rapid progress of these vaccines was not achieved by compromising compliance; rather, it was made possible by the seamless integration of technology, global collaboration, and regulatory alignment.
Ultimately, disruptive innovation and regulatory compliance are not at odds. When approached strategically, they complement each other, driving faster breakthroughs while safeguarding the safety, quality, and public trust that are essential in healthcare.
9. In what ways is innovation in bioprocessing facilitating the development of personalized therapies, and what challenges remain in scaling these solutions?
The rise of targeted, patient-specific therapies, particularly cell and gene therapies, is redefining how we approach bioprocessing. In recent years, innovations in this space have been central to making personalised medicine both feasible and clinically impactful. Single-use technologies, automated cell-handling platforms, and closed-system manufacturing have dramatically reduced contamination risks and variability, critical factors when each batch is uniquely tailored to an individual patient.
AI-driven analytics and real-time monitoring further optimise small-volume, high-complexity processes by predicting cell behaviour and enhancing consistency across manufacturing runs. Meanwhile, emerging tools such as 3D bioprinting, next-generation gene editing, and digitalised CAR-T production workflows are creating new opportunities to deliver therapies with unprecedented precision, reliability, and patient-specific customisation.
Despite these advances, scaling personalised therapies remains one of the industry’s biggest challenges. Manufacturing continues to face manual workflows, high production costs, and operational bottlenecks that hinder the rapid turnaround of patient-specific batches. Global capacity is limited, and achieving standardisation across sites is difficult for processes that, by nature, vary with each individual patient.
10. What skill sets and leadership approaches are critical for driving innovation in bioprocessing and fostering a culture of continuous improvement?
Driving innovation and continuous improvement in bioprocessing requires blending advanced technical expertise with leadership strategies that foster a supportive, collaborative, and adaptable culture. Today’s bioprocessing professionals must combine traditional scientific knowledge with emerging digital capabilities. Proficiency in automation, data analytics, AI, and process modeling is becoming as essential as expertise in cell culture, downstream purification, or regulatory science. Equally important is the ability to collaborate across disciplines, engineering, biology, digital, and quality, making cross-functional teamwork a core competency rather than a specialised skill.
Leadership is pivotal in shaping this culture. Today’s successful bioprocessing leaders are more than decision-makers; they are enablers. They cultivate psychological safety to encourage new ideas, champion cross-functional collaboration, and support experimentation, all while maintaining operational rigour. They empower teams to innovate independently, while ensuring accountability, knowledge sharing, and strict adherence to regulatory standards.
11. How can organisations leverage real-time process data and analytics to improve product quality and regulatory compliance?
Technological advancements are providing organisations with powerful tools to enhance product quality and operational reliability. Alongside this progress, however, come higher expectations for transparency, data integrity, and regulatory compliance. As a result, companies are moving from manual, labour-intensive compliance efforts to real-time, technology-driven systems that make oversight faster, clearer, and far more reliable.
Today, real-time process data is central to improving both product quality and regulatory confidence. Organisations can continuously monitor critical parameters, detect emerging trends as they happen, and implement timely adjustments to safeguard quality. When paired with advanced analytics and modelling, this data provides deeper process insights, enables early anomaly detection, and helps maintain consistent performance across every run.
From a regulatory perspective, real-time analytics are reshaping how organisations manage risk and demonstrate compliance. They enable more structured, transparent, and defensible data ecosystems. Capabilities such as automated audit trails, intelligent event classification, real-time alerts, and risk insights allow teams to maintain compliance with less reliance on manual oversight.
By collecting and analysing data across systems, integrated analytics frameworks strengthen data integrity and enhance regulatory readiness, supporting more consistent and confident regulatory engagement.
12. Beyond AI, what other emerging technologies (e.g., continuous manufacturing, single-use systems, digital twins) are poised to redefine bioprocessing?
The next wave of innovation in bioprocessing is being driven by technologies that are redefining how manufacturing systems are designed, scaled, and operated. Beyond AI, several advancements are moving the industry toward more flexible, connected, and resilient production models. One of the most notable shifts is the adoption of continuous manufacturing, which replaces traditional batch processes with seamless, end-to-end production. This approach shortens timelines, enhances consistency, and enables real-time adjustments. At the same time, single-use systems are expanding their impact, facilitating faster changeovers, reducing contamination risk, and providing greater agility, especially for multi-product facilities and personalized therapies.
Digital twins are rapidly gaining traction in bioprocessing. By creating virtual replicas of processes that operate on real-time data, manufacturers can simulate changes, predict outcomes, and optimise operations without disrupting production. This capability not only enhances decision-making but also accelerates process development and scaling.
Complementing these advances are next-generation PAT tools, automation, robotics, and IoT-enabled infrastructures, all of which deliver greater precision, enhanced connectivity, and improved process control. Innovations in bioreactor design, membrane chromatography, and even 3D-printed components are further driving the shift toward modular, intensified, and continuous platforms, capable of supporting both large-scale biologics and personalised therapies.
13. How do you envision the next decade of bioprocessing evolving, particularly in terms of speed, accessibility, and patient impact?
Bioprocessing is moving toward a future where speed and flexibility are becoming the norm rather than a trade-off. Continuous, connected, and intensified processing approaches are increasingly being combined with automation, real-time analytics, and advanced control systems, making the transition from lab-scale development to large-scale manufacturing faster, more predictable, and more efficient.
As a result, smaller and more intelligent facilities will be able to produce biologics more rapidly, reducing both capital and operating costs while maintaining high standards of consistency and quality.
At the same time, this shift is poised to significantly enhance accessibility and patient impact. As manufacturing becomes more efficient, modular, and continuous, biologics can become more affordable, and patients can receive life-saving therapies more quickly. Platforms help standardize processes across scales and geographies, lowering barriers for emerging biotechs and CDMOs to deliver complex therapies to patients around the world.
Looking ahead, I envision bioprocessing evolving into a fully ‘smart manufacturing’ ecosystem, where dynamic control, digital connectivity, and adaptive scaling allow rapid responses to emerging health needs. This approach will accelerate development and production cycles, reduce failure rates, and make it possible to deliver advanced therapies to patients more reliably, efficiently, and cost-effectively than ever before.
14. Finally, from a thought leadership perspective, what advice would you give to executives seeking to stay ahead of innovation trends in biopharma manufacturing?
The biggest risk today is not moving too fast—it’s moving in fragments. My first advice is to stop treating process innovation, digitalisation, and talent as separate conversations. Continuous, intensified, and connected bioprocessing, supported by AI and advanced analytics, should be viewed as one integrated strategy that spans from early development to commercial supply.
Second, leaders need to embrace data and AI not just as tools, but as a new management discipline. Digital twins, real‑time analytics, and AI‑enabled control are already changing how we run bioreactors, manage variability, and prevent failures. The organisations that will lead are those that build the structures—governance, data standards, cross‑functional teams— that allow these capabilities to scale across sites and modalities, rather than remain as pilots in isolated facilities.
Finally, staying ahead is fundamentally about ecosystems: people, partnerships, and platforms. Executives should invest in developing talent that is fluent in both science and digital, create cultures where experimentation is encouraged but quality and compliance are non‑negotiable, and lean into collaboration—with startups, academia, CDMOs, technology partners, and policymakers. The companies that will shape the future of bioprocessing are those that treat innovation not as a series of one‑off projects, but as a long‑term commitment to re‑imagining how medicines are made and delivered to patients, end to end.
